Physician profile
John H White
NPI 1053343186
$2,816.92
in general payments reported to CMS, 2019-2025
28 companies · $722 in 2025
The $722 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $84.58 · 2021: $99.95 · 2022: $238 · 2023: $518 · 2024: $609 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,764 · Education: $85.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,764.05 |
| Education | $85.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $615.59 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $340.46 | 2019-2025 | |
| Astellas Pharma US INC | $218.25 | 2021-2025 | Xtandi |
| Janssen Biotech, INC. | $182.92 | 2019-2020 | |
| Cook Medical LLC | $181.87 | 2023-2024 | Litho 150, Cook, Fiber Dust |
| Abbvie INC. | $165.83 | 2019-2025 | Botox |
| Myovant Sciences INC. | $138.55 | 2022 | |
| Endo Pharmaceuticals INC. | $136.19 | 2019-2024 | Xiaflex |
| Recordati_rare_diseases_inc. | $124.40 | 2025 | Sylvant |
| Tolmar, INC. | $77.89 | 2025 | Jatenzo, Eligard |
| Ferring Pharmaceuticals INC. | $75.69 | 2025 | Adstiladrin |
| 180 Medical, INC. | $71.32 | 2019-2024 | |
| Boston Scientific Corporation | $64.85 | 2019-2024 | Advantage System |
| Antares Pharma, INC. | $64.13 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Medtronic, INC. | $61.03 | 2024 | Interstim |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $42.00 | 2023 | Speedicath |
| Procept Biorobotics Corporation | $41.12 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.23 | 2020-2024 | |
| Laborie Medical Technologies Corp. | $24.26 | 2025 | |
| Halozyme INC | $21.65 | 2023 | |
| Travere Therapeutics, INC. | $20.65 | 2019 | |
| Urovant Sciences INC | $19.54 | 2022 | |
| Urogen Pharma, INC. | $19.16 | 2025 | |
| Amgen INC. | $18.42 | 2019 | |
| Neotract INC. | $16.81 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $16.07 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $14.73 | 2022 | |
| Eagle Pharmaceuticals, INC. | $14.31 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.